AllRock Bio’s drug is a small molecule pan-ROCK inhibitor ready for Phase 2 testing in pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease. The startup is led by the management team that steered CinCor Pharma to a $1.3 billion acquisition by AstraZeneca.
The FDA decision for Tyvaso as a treatment for pulmonary arterial hypertension in patients who have interstitial lung disease is the second approval for the United Therapeutics drug. The additional indication gives the company another way to grow revenue for the drug, which faces generic competition.
We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring.